UBS O'Connor’s Regenxbio RGNX Stock Holding History

UBS O'Connor’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-80,000	Closed	-$30K	–	435
2024 Q4	$30K	Buy	+80,000	New	+$751K	﹤0.01%	377

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS O'Connor's RGNX Position: Q3 2024 in Review

UBS O'Connor sold out of Regenxbio (RGNX) in Q3 2024, closing a stake of 70,199 shares — an estimated $821K sold.

UBS O'Connor first reported a position in RGNX in Q1 2017 and held it in 2 quarters. The position peaked at $2.58M in Q1 2017. 186 funds tracked by Wall St. Rank hold RGNX as of Q3 2024.

UBS O'Connor reported no remaining Regenxbio position as of Q3 2024 after selling out during the quarter.
UBS O'Connor sold 70,199 Regenxbio shares in Q3 2024, an estimated $821K.
UBS O'Connor first reported a position in Regenxbio in Q1 2017 and held it in 2 quarters.
UBS O'Connor's Regenxbio position peaked at $2.58M in Q1 2017.
186 funds tracked by Wall St. Rank held Regenxbio as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.